Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

Investors may be wondering whether Haemonetics at around US$74 is offering value right now, or whether the market is still undecided about its future potential. The stock has been quite mixed lately, ...

The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular ...

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

The ELITE arterial study demonstrated ease of use for Vivasure's PerQseal Elite with no need for pre-close.

We believe that the stock price of Haemonetics (NYSE: HAE), best known for its blood and plasma supplies and services, is undervalued at current levels of $63. HAE stock is down 27% from the levels of ...

Haemonetics' acquisition of Vivasure adds PerQseal Elite, advancing large-bore closure solutions for TAVR and EVAR markets.

Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.

Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

BOSTON, Oct. 6, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, ...

BOSTON, March 2, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible ...